Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Core Viewpoint - Olema Pharmaceuticals' stock surged significantly following positive phase 3 results from Roche's giredestrant study for early-stage breast cancer, indicating strong market interest and potential in the SERD drug sector [1][3]. Stock Performance - Olema Pharmaceuticals shares increased by 136.8%, reaching $20.17 during midday trading on Tuesday [3]. - The stock's rise was in stark contrast to Martin Shkreli's short position declaration, which suggested skepticism about Olema's valuation [1][2]. Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Emily Bodnar maintained a Buy rating and raised the price target from $28 to $36 [4]. - Oppenheimer analyst Matthew Biegler kept an Outperform rating and increased the price target from $22 to $45 [4]. - JPMorgan maintained an Overweight rating and raised the price target from $29 to $32 [4]. Market Context - Shkreli criticized the overcrowded SERD market, implying that Olema's high valuation was unwarranted, yet the stock's performance suggests a differing market sentiment [2][3].